AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33300448 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention group (n = 35)
Number of subjects: 71
Study 33300448 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 71
Study 33300448 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy reports from parents in VR group (n = 35)
Number of subjects: 71
Study 33300448 — intervention group
Group type: COMPARATOR
Intervention: Proxy reports from parents in control group (n = 36)
Number of subjects: 71
Study 33198689 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-informed and user-centered information campaign including posters, leaflets, adverts, and films displayed in various media.
Number of subjects: 0
Study 33198689 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-informed and user-centered information campaign.
Number of subjects: 0
Study 33198689 — intervention group
Group type: COMPARATOR
Intervention: Control county (no campaign).
Number of subjects: 0
Study 35738644 — intervention group
Group type: EXPERIMENTAL
Intervention: RehaCAT+ (web-based computer-adaptive patient-reported outcome test platform)
Number of subjects: 1848
Study 35738644 — intervention group
Group type: COMPARATOR
Intervention: RehaCAT (standard diagnostic system)
Number of subjects: 1848
Study 33039853 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Therapy + Expiratory Flow Acceleration (EFA)
Number of subjects: 25
Study 33039853 — intervention group
Group type: COMPARATOR
Intervention: Standard Therapy (ST)
Number of subjects: 25
Study 36114808 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 17
Study 32031466 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified‐Krishnan’s frailty index (FI)
Number of subjects: 130
Study 32031466 — intervention group
Group type: EXPERIMENTAL
Intervention: CSHA frailty index (FI)
Number of subjects: 130
Study 34843078 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (0.1 ug/kg) combined with propofol
Number of subjects: 224
Study 34843078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.1 mg/kg) combined with propofol
Number of subjects: 224
Study 34843078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Sufentanil and Nalbuphine)
Number of subjects: 224
Study 35949399 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR arm (ethambutol discontinued if no resistance detected)
Number of subjects: 203
Study 35949399 — intervention group
Group type: COMPARATOR
Intervention: C arm (standard 4-drug combination pending phenotypic results)
Number of subjects: 203
Study 33331917 — intervention group
Group type: COMPARATOR
Intervention: Plasma Aβ42/40 ratio greater than 0.107
Number of subjects: 483
Study 35575454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided suprascapular nerve blocks with ropivacaine 5 mL 2 mg/mL
Number of subjects: 35
Study 35575454 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided injections of 5 mL sterile saline solution (NaCl 0.9%)
Number of subjects: 35
Study 34753541 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics combined with ABA intervention
Number of subjects: 41
Study 34753541 — intervention group
Group type: COMPARATOR
Intervention: ABA intervention alone (Control)
Number of subjects: 41
Study 33185374 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline injection while supine (A group)
Number of subjects: 44
Study 33185374 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline injection in sitting position (B group)
Number of subjects: 44
Study 33185374 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups A and B
Number of subjects: 44
Study 33340285 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 77
Study 33340285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 33666540 — intervention group
Group type: EXPERIMENTAL
Intervention: TP 3‐in‐1™ juice (n = 16)
Number of subjects: 31
Study 33666540 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 31
Study 35141485 — intervention group
Group type: EXPERIMENTAL
Intervention: AFO with plantar flexion stop (AFO‐PlfS)
Number of subjects: 20
Study 35141485 — intervention group
Group type: EXPERIMENTAL
Intervention: AFO with plantar flexion resistance (AFO‐PlfR)
Number of subjects: 20
Study 36426764 — intervention group
Group type: EXPERIMENTAL
Intervention: Wondaleaf female condom
Number of subjects: 220
Study 36426764 — intervention group
Group type: COMPARATOR
Intervention: FC2 female condom
Number of subjects: 220
Study 35210180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity continuous training
Number of subjects: 48
Study 35210180 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training
Number of subjects: 48
Study 35210180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 48
Study 35210180 — intervention group
Group type: COMPARATOR
Intervention: Control (Sedentary group)
Number of subjects: 48
Study 35881420 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (fosinopril or hydrochlorothiazide alone or combined with a statin)
Number of subjects: 470
Study 33404758 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplemented with 107 CFU/mL of Lactobacillus rhamnosus SP1
Number of subjects: 42
Study 33404758 — intervention group
Group type: COMPARATOR
Intervention: Standard milk (Control)
Number of subjects: 42
Study 32119192 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 59
Study 32119192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 33342316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion-time hypertension trials following minimum guidelines for treatment timing based on internal biological time (morning vs evening) and assessed using ABPM.
Number of subjects: 0
Study 33342316 — intervention group
Group type: EXPERIMENTAL
Intervention: ABPM as the primary or sole method of BP assessment.
Number of subjects: 0
Study 33342316 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum required features for analysis of ABPM-determined 24 h BP pattern including asleep BP mean and sleep-time relative BP decline.
Number of subjects: 0
Study 33342316 — intervention group
Group type: EXPERIMENTAL
Intervention: ABPM performed with validated devices at least hourly throughout two or more consecutive 24 h periods.
Number of subjects: 0
Study 33342316 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculation of minimum required sample size using proper statistical methods.
Number of subjects: 0
Study 33342316 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension chronopharmacology and chronotherapy trials should preferably be randomized double-blind, randomized open-label with blinded-endpoint, or crossover in design.
Number of subjects: 0
Study 33059620 — intervention group
Group type: EXPERIMENTAL
Intervention: QFT conversion using manufacturers' definition (def1)
Number of subjects: 2187
Study 33059620 — intervention group
Group type: EXPERIMENTAL
Intervention: QFT conversion using stricter definition (def2)
Number of subjects: 2187
Study 33059620 — intervention group
Group type: EXPERIMENTAL
Intervention: QFT conversion using stricter definition (def3)
Number of subjects: 2187
Study 33059620 — intervention group
Group type: EXPERIMENTAL
Intervention: QFT conversion using stricter definition (def4)
Number of subjects: 2187
Study 33059620 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HIV positive not on antiretroviral treatment to HIV negative using def1
Number of subjects: 2187
Study 33038532 — intervention group
Group type: EXPERIMENTAL
Intervention: KH‐ePVS
Number of subjects: 6373
Study 33038532 — intervention group
Group type: EXPERIMENTAL
Intervention: Duarte‐ePV
Number of subjects: 6373
Study 32408868 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar-based yoga intervention (twice weekly group classes and once weekly home practice for 12 weeks)
Number of subjects: 27
Study 35509178 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-based contrast agents
Number of subjects: 1404
Study 35509178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram prediction model
Number of subjects: 1404
Study 34797962 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira)
Number of subjects: 720
Study 34797962 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 720
Study 34797962 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 720
Study 32876755 — intervention group
Group type: EXPERIMENTAL
Intervention: SAP P11-4 (Curodont Repair, Windisch, Switzerland) applied and stored for 24 hours in artificial saliva
Number of subjects: 45
Study 32876755 — intervention group
Group type: EXPERIMENTAL
Intervention: SAP P11-4 applied
Number of subjects: 45
Study 32876755 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment with SAP P11-4 (control group)
Number of subjects: 45
Study 36053298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral OXT (24 IU)
Number of subjects: 80
Study 36053298 — intervention group
Group type: COMPARATOR
Intervention: Intranasal OXT
Number of subjects: 80
Study 36053298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35238791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) combined with machine learning methods
Number of subjects: 45
Study 35238791 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning classifiers using EMA data
Number of subjects: 45
Study 35238791 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning methods
Number of subjects: 45
Study 34328570 — intervention group
Group type: EXPERIMENTAL
Intervention: BI plus CETA
Number of subjects: 160
Study 34328570 — intervention group
Group type: COMPARATOR
Intervention: BI alone
Number of subjects: 160
Study 33164692 — intervention group
Group type: EXPERIMENTAL
Intervention: Del Nido cardioplegia
Number of subjects: 100
Study 33164692 — intervention group
Group type: COMPARATOR
Intervention: BSTH cardioplegia
Number of subjects: 100
Study 34087678 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) during exercise
Number of subjects: 14
Study 34087678 — intervention group
Group type: COMPARATOR
Intervention: Sham ventilation
Number of subjects: 14
Study 32170259 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning approach based on an e-learning resource
Number of subjects: 70
Study 32170259 — intervention group
Group type: COMPARATOR
Intervention: Control group with no prior teaching
Number of subjects: 70
Study 32170259 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning approach
Number of subjects: 70
Study 32170259 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 615916337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 33
Study 615916337 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 33
Study 615916337 — intervention group
Group type: EXPERIMENTAL
Intervention: No morphological abnormalities
Number of subjects: 33
Study 615916337 — intervention group
Group type: EXPERIMENTAL
Intervention: External limiting membrane disruption
Number of subjects: 33
Study 36227461 — intervention group
Group type: EXPERIMENTAL
Intervention: VT substrate ablation (ABLATE arm)
Number of subjects: 0
Study 36227461 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical treatment (OMT arm)
Number of subjects: 0
Study 36227461 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-guided ablation
Number of subjects: 0
Study 33357480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance (15 mg per day for platelets >100×10^9 cells/L or 10 mg per day for platelets 60-100×10^9 cells/L, days 1-21 every 28 days) for 24 months
Number of subjects: 300
Study 33357480 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 300
Study 33357480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 300
Study 32988822 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Infusion (CI) of cloxacillin (two 75-mg/kg 12-h infusions per day for 3 days)
Number of subjects: 11
Study 32988822 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Infusion (ItI) of cloxacillin (four 37.5-mg/kg 1-h infusions per day for 3 days)
Number of subjects: 11
Study 35759680 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐days clotrimazole 2% vaginal cream once‐daily plus 15‐days concomitant acid pH thymol and zinc‐containing cleansing wash (SaugellaActi3) twice‐daily
Number of subjects: 200
Study 35759680 — intervention group
Group type: COMPARATOR
Intervention: 6‐days clotrimazole treatment alone
Number of subjects: 200
Study 34493259 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention using motivational interviewing and principles of cognitive‐behavioral therapy
Number of subjects: 928
Study 34493259 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 928
Study 33142988 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to commercial messages advertising food products
Number of subjects: 421
Study 33142988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugared cereals (first product pair)
Number of subjects: 421
Study 33142988 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate cookies (second product pair)
Number of subjects: 421
Study 33142988 — intervention group
Group type: EXPERIMENTAL
Intervention: Filled rolls (last product pair)
Number of subjects: 421
Study 616737684 — intervention group
Group type: EXPERIMENTAL
Intervention: REFOCUS intervention
Number of subjects: 37
Study 36166727 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination nivolumab/ipilimumab (arm A)
Number of subjects: 265
Study 36166727 — intervention group
Group type: COMPARATOR
Intervention: Dabrafenib/trametinib (arm B)
Number of subjects: 265
Study 36166727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib/trametinib (arm C)
Number of subjects: 265
Study 36166727 — intervention group
Group type: COMPARATOR
Intervention: Combination nivolumab/ipilimumab (arm D)
Number of subjects: 265
Study 36166727 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover (between arms)
Number of subjects: 265
Study 36166727 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 265
Study 32656799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, lenalidomide, and dexamethasone (CRDa)
Number of subjects: 0
Study 32656799 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, thalidomide, and dexamethasone (CTDa)
Number of subjects: 0
Study 32656799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing therapy with lenalidomide
Number of subjects: 0
Study 32656799 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 32697308 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethyl cellulose hydrofiber dressing with ionized silver (CMCH‐Ag)
Number of subjects: 0
Study 32697308 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene-polyethylene terephthalate aqua fiber dressing with elementary silver (PPAF‐Ag)
Number of subjects: 0
Study 32697308 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate (CA)
Number of subjects: 0
Study 32697308 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + zinc alginate (CZA)
Number of subjects: 0
Study 32697308 — intervention group
Group type: COMPARATOR
Intervention: 0.2% nitrofurazone‐embedded (NF) gauze dressings
Number of subjects: 0
Study 35197350 — intervention group
Group type: EXPERIMENTAL
Intervention: General Practitioner services in emergency departments (GPEDs)
Number of subjects: 4441349
Study 35197350 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GPED services)
Number of subjects: 4441349
Study 34101953 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified care
Number of subjects: 333
Study 34101953 — intervention group
Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 333
Study 32699180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction (DSR) with a low sodium target of 50 mmol/day
Number of subjects: 13
Study 34183770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk enriched with extensively hydrolyzed protein (high protein group)
Number of subjects: 56
Study 34183770 — intervention group
Group type: COMPARATOR
Intervention: Fortified milk without additional protein (standard protein group)
Number of subjects: 56
Study 34676600 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamidol (applied daily in Dual Serum followed by Day Care SPF30 or Night Care)
Number of subjects: 48
Study 34676600 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamidol
Number of subjects: 48
Study 34676600 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (applied daily in corresponding vehicle formulations)
Number of subjects: 48
Study 35331406 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 5988
Study 35331406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5988
Study 33210408 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumagalactomannosides (CGM) 400 mg once daily
Number of subjects: 72
Study 33210408 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine hydrochloride (GLN) 500 mg and Chondroitin sulphate (CHN) 415 mg, supplied as a single oral dose twice a day
Number of subjects: 72
Study 34102278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance therapy intervention
Number of subjects: 0
Study 34102278 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy intervention
Number of subjects: 0
Study 37793976 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 87
Study 37793976 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV15
Number of subjects: 87
Study 34309766 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body MRI with diffusion-weighted imaging (DWIBS)
Number of subjects: 52
Study 32251871 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain death exposure
Number of subjects: 1072
Study 32251871 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulatory death exposure
Number of subjects: 1072
Study 35421449 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 COVID-19 vaccine
Number of subjects: 505
Study 33561279 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating Current (AC) at 2.5 kHz, pulse duration = 0.4 milliseconds, burst frequency = 100 Hz
Number of subjects: 30
Study 33561279 — intervention group
Group type: COMPARATOR
Intervention: Pulsed Current (PC), pulse duration = 2 milliseconds, pulse frequency = 100 Hz
Number of subjects: 30
Study 32623925 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted mean arterial pressure (MAP)
Number of subjects: 408228
Study 32623925 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted pulse pressure (PP)
Number of subjects: 408228
Study 32623925 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted MAP
Number of subjects: 408228
Study 32623925 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted PP
Number of subjects: 408228
Study 32623925 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted MAP and PP
Number of subjects: 408228
Study 35915733 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture along meridians
Number of subjects: 96
Study 35915733 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine and massage therapy
Number of subjects: 96
Study 33882526 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel
Number of subjects: 0
Study 33882526 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet chemotherapy
Number of subjects: 0
Study 33882526 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (single agents or in combination)
Number of subjects: 0
Study 34463423 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14543
Study 34463423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14543
Study 34127033 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced information group (standard information plus video)
Number of subjects: 521
Study 34127033 — intervention group
Group type: COMPARATOR
Intervention: Standard information group (patient information and diagrams)
Number of subjects: 521
Study 32638504 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 947
Study 32638504 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 947
Study 32638504 — intervention group
Group type: COMPARATOR
Intervention: MTX (7.5-20 mg/week)
Number of subjects: 947
Study 35870875 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Vivifrail multicomponent exercise program and personalized executive function-based cognitive training (VIVIFRAIL-COGN)
Number of subjects: 320
Study 35870875 — intervention group
Group type: COMPARATOR
Intervention: Usual care delivered in the Falls Units, including the Otago Exercise Program
Number of subjects: 320
Study 33773984 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intracanalicular insert
Number of subjects: 30
Study 33773984 — intervention group
Group type: COMPARATOR
Intervention: Placebo insert
Number of subjects: 30
Study 33105375 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear LIST
Number of subjects: 8
Study 33105375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear LIST
Number of subjects: 8
Study 33105375 — intervention group
Group type: COMPARATOR
Intervention: Both conditions
Number of subjects: 8
Study 34020578 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LTZ)
Number of subjects: 0
Study 34020578 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 0
Study 34020578 — intervention group
Group type: COMPARATOR
Intervention: Control (laparoscopy alone)
Number of subjects: 0
Study 33298617 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 195
Study 33298617 — intervention group
Group type: COMPARATOR
Intervention: Nontocilizumab
Number of subjects: 195
Study 35676287 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) 3 times/week
Number of subjects: 47
Study 35676287 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 47